Global Soliris Drug
Global Soliris Drug

Soliris Drug Comprehensive Study by Type (Plasma Exchange, Plasma Infusion), Application (PNH, AHUS, HPP, GMG, Other), End-User (Pharmaceutical, Hospital, R&D labs, Others) Players and Region - Global Market Outlook to 2027

Soliris Drug Market Segmented into XX Submarkets. | Forecast Years: 2022- 2027  

Mar 2022 Edition 232 Pages 63 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Soliris Drug Market Scope?
Soliris is a prescription medication used to treat the symptoms of PNH, HUS, Myasthenia Gravis, and Neuromyelitis Optical Spectrum Disorder. Soliris can be taken on its own or in combination with other drugs. Soliris belongs to the Monoclonal Antibodies family of medicines. It is only prescribed to those who have enrolled in and follow a risk evaluation and mitigation strategy, which includes counseling and ensuring that they are vaccinated, and it is only prescribed to those who have enrolled in and follow a risk evaluation and mitigation strategy, which includes counseling and ensuring that they are vaccinated.

The Soliris Drug market study is being classified by Type (Plasma Exchange and Plasma Infusion), by Application (PNH, AHUS, HPP, gMG and Other) and major geographies with country level break-up.

The Soliris drug market is extremely competitive, with several large firms. The Alexion is the major manufacturing company which contributes their share for growing the market. Mergers and acquisitions, expansions, investments, new service launches, and collaborations are some of the companies' preferred market-exploration strategies. To get a competitive advantage through synergy, players are growing and acquiring businesses in new geographies.

Alexion (United States), Company 2, Company 3, Company 4 and Company 5 are some of the key players profiled in the study.

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Soliris Drug market by Type, Application and Region.

On the basis of geography, the market of Soliris Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

In Nov 2020, With Genentech, Genesis Therapeutics has formed an AI-driven, multi-target drug discovery relationship. Genesis' graph machine learning and drug discovery skills will be used in this cooperation to identify novel drug candidates for therapeutic targets in a variety of illness domains.


Market Drivers
  • Increasing Demand in the Biologics Market
  • Increasing Cases of Anemia in Developing Countries

Opportunities
  • Self-Administration and Home Care

Restraints
  • Health Issues

Challenges
  • Strict Government Guidelines Related To Drugs
  • Pricing Pressure


Key Target Audience
Soliris Drug Manufacturers, Industry Association, Downstream Vendors, Marketing & Consulting firms, Venture Capitalists, Government & Regulatory Bodies and Traders/Suppliers & Distributors

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Frequently Asked Questions (FAQ):

1. At what growth rate would the Soliris Drug market expands?
The Global Soliris Drug market is expected to see a growth of % during projected year 2021 to 2027.

2. Who are the prominent players of the Global Soliris Drug market?
The prominent players of Global Soliris Drug market are Alexion (United States), Company 2, Company 3, Company 4 and Company 5, to name a few.

3. What are the top priorities to focus for Soliris Drug marketís growth?
In this highly competitive & fast evolving Soliris Drug industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.
Report Objectives / Segmentation Covered
By Type
  • Plasma Exchange
  • Plasma Infusion
By Application
  • PNH
  • AHUS
  • HPP
  • gMG
  • Other
By End-User
  • Pharmaceutical
  • Hospital
  • R&D labs
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Demand in the Biologics Market
      • 3.2.2. Increasing Cases of Anemia in Developing Countries
    • 3.3. Market Challenges
      • 3.3.1. Strict Government Guidelines Related To Drugs
      • 3.3.2. Pricing Pressure
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Soliris Drug, by Type, Application, End-User and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Soliris Drug (Value)
      • 5.2.1. Global Soliris Drug by: Type (Value)
        • 5.2.1.1. Plasma Exchange
        • 5.2.1.2. Plasma Infusion
      • 5.2.2. Global Soliris Drug by: Application (Value)
        • 5.2.2.1. PNH
        • 5.2.2.2. AHUS
        • 5.2.2.3. HPP
        • 5.2.2.4. GMG
        • 5.2.2.5. Other
      • 5.2.3. Global Soliris Drug by: End-User (Value)
        • 5.2.3.1. Pharmaceutical
        • 5.2.3.2. Hospital
        • 5.2.3.3. R&D labs
        • 5.2.3.4. Others
      • 5.2.4. Global Soliris Drug Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Soliris Drug (Price)
      • 5.3.1. Global Soliris Drug by: Type (Price)
  • 6. Soliris Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Alexion (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Company 2
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Company 3
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Company 4
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Company 5
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
  • 7. Global Soliris Drug Sale, by Type, Application, End-User and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Soliris Drug (Value)
      • 7.2.1. Global Soliris Drug by: Type (Value)
        • 7.2.1.1. Plasma Exchange
        • 7.2.1.2. Plasma Infusion
      • 7.2.2. Global Soliris Drug by: Application (Value)
        • 7.2.2.1. PNH
        • 7.2.2.2. AHUS
        • 7.2.2.3. HPP
        • 7.2.2.4. GMG
        • 7.2.2.5. Other
      • 7.2.3. Global Soliris Drug by: End-User (Value)
        • 7.2.3.1. Pharmaceutical
        • 7.2.3.2. Hospital
        • 7.2.3.3. R&D labs
        • 7.2.3.4. Others
      • 7.2.4. Global Soliris Drug Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Soliris Drug (Price)
      • 7.3.1. Global Soliris Drug by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Soliris Drug: by Type(USD Million)
  • Table 2. Soliris Drug Plasma Exchange , by Region USD Million (2016-2021)
  • Table 3. Soliris Drug Plasma Infusion , by Region USD Million (2016-2021)
  • Table 4. Soliris Drug: by Application(USD Million)
  • Table 5. Soliris Drug PNH , by Region USD Million (2016-2021)
  • Table 6. Soliris Drug AHUS , by Region USD Million (2016-2021)
  • Table 7. Soliris Drug HPP , by Region USD Million (2016-2021)
  • Table 8. Soliris Drug GMG , by Region USD Million (2016-2021)
  • Table 9. Soliris Drug Other , by Region USD Million (2016-2021)
  • Table 10. Soliris Drug: by End-User(USD Million)
  • Table 11. Soliris Drug Pharmaceutical , by Region USD Million (2016-2021)
  • Table 12. Soliris Drug Hospital , by Region USD Million (2016-2021)
  • Table 13. Soliris Drug R&D labs , by Region USD Million (2016-2021)
  • Table 14. Soliris Drug Others , by Region USD Million (2016-2021)
  • Table 15. South America Soliris Drug, by Country USD Million (2016-2021)
  • Table 16. South America Soliris Drug, by Type USD Million (2016-2021)
  • Table 17. South America Soliris Drug, by Application USD Million (2016-2021)
  • Table 18. South America Soliris Drug, by End-User USD Million (2016-2021)
  • Table 19. Brazil Soliris Drug, by Type USD Million (2016-2021)
  • Table 20. Brazil Soliris Drug, by Application USD Million (2016-2021)
  • Table 21. Brazil Soliris Drug, by End-User USD Million (2016-2021)
  • Table 22. Argentina Soliris Drug, by Type USD Million (2016-2021)
  • Table 23. Argentina Soliris Drug, by Application USD Million (2016-2021)
  • Table 24. Argentina Soliris Drug, by End-User USD Million (2016-2021)
  • Table 25. Rest of South America Soliris Drug, by Type USD Million (2016-2021)
  • Table 26. Rest of South America Soliris Drug, by Application USD Million (2016-2021)
  • Table 27. Rest of South America Soliris Drug, by End-User USD Million (2016-2021)
  • Table 28. Asia Pacific Soliris Drug, by Country USD Million (2016-2021)
  • Table 29. Asia Pacific Soliris Drug, by Type USD Million (2016-2021)
  • Table 30. Asia Pacific Soliris Drug, by Application USD Million (2016-2021)
  • Table 31. Asia Pacific Soliris Drug, by End-User USD Million (2016-2021)
  • Table 32. China Soliris Drug, by Type USD Million (2016-2021)
  • Table 33. China Soliris Drug, by Application USD Million (2016-2021)
  • Table 34. China Soliris Drug, by End-User USD Million (2016-2021)
  • Table 35. Japan Soliris Drug, by Type USD Million (2016-2021)
  • Table 36. Japan Soliris Drug, by Application USD Million (2016-2021)
  • Table 37. Japan Soliris Drug, by End-User USD Million (2016-2021)
  • Table 38. India Soliris Drug, by Type USD Million (2016-2021)
  • Table 39. India Soliris Drug, by Application USD Million (2016-2021)
  • Table 40. India Soliris Drug, by End-User USD Million (2016-2021)
  • Table 41. South Korea Soliris Drug, by Type USD Million (2016-2021)
  • Table 42. South Korea Soliris Drug, by Application USD Million (2016-2021)
  • Table 43. South Korea Soliris Drug, by End-User USD Million (2016-2021)
  • Table 44. Taiwan Soliris Drug, by Type USD Million (2016-2021)
  • Table 45. Taiwan Soliris Drug, by Application USD Million (2016-2021)
  • Table 46. Taiwan Soliris Drug, by End-User USD Million (2016-2021)
  • Table 47. Australia Soliris Drug, by Type USD Million (2016-2021)
  • Table 48. Australia Soliris Drug, by Application USD Million (2016-2021)
  • Table 49. Australia Soliris Drug, by End-User USD Million (2016-2021)
  • Table 50. Rest of Asia-Pacific Soliris Drug, by Type USD Million (2016-2021)
  • Table 51. Rest of Asia-Pacific Soliris Drug, by Application USD Million (2016-2021)
  • Table 52. Rest of Asia-Pacific Soliris Drug, by End-User USD Million (2016-2021)
  • Table 53. Europe Soliris Drug, by Country USD Million (2016-2021)
  • Table 54. Europe Soliris Drug, by Type USD Million (2016-2021)
  • Table 55. Europe Soliris Drug, by Application USD Million (2016-2021)
  • Table 56. Europe Soliris Drug, by End-User USD Million (2016-2021)
  • Table 57. Germany Soliris Drug, by Type USD Million (2016-2021)
  • Table 58. Germany Soliris Drug, by Application USD Million (2016-2021)
  • Table 59. Germany Soliris Drug, by End-User USD Million (2016-2021)
  • Table 60. France Soliris Drug, by Type USD Million (2016-2021)
  • Table 61. France Soliris Drug, by Application USD Million (2016-2021)
  • Table 62. France Soliris Drug, by End-User USD Million (2016-2021)
  • Table 63. Italy Soliris Drug, by Type USD Million (2016-2021)
  • Table 64. Italy Soliris Drug, by Application USD Million (2016-2021)
  • Table 65. Italy Soliris Drug, by End-User USD Million (2016-2021)
  • Table 66. United Kingdom Soliris Drug, by Type USD Million (2016-2021)
  • Table 67. United Kingdom Soliris Drug, by Application USD Million (2016-2021)
  • Table 68. United Kingdom Soliris Drug, by End-User USD Million (2016-2021)
  • Table 69. Netherlands Soliris Drug, by Type USD Million (2016-2021)
  • Table 70. Netherlands Soliris Drug, by Application USD Million (2016-2021)
  • Table 71. Netherlands Soliris Drug, by End-User USD Million (2016-2021)
  • Table 72. Rest of Europe Soliris Drug, by Type USD Million (2016-2021)
  • Table 73. Rest of Europe Soliris Drug, by Application USD Million (2016-2021)
  • Table 74. Rest of Europe Soliris Drug, by End-User USD Million (2016-2021)
  • Table 75. MEA Soliris Drug, by Country USD Million (2016-2021)
  • Table 76. MEA Soliris Drug, by Type USD Million (2016-2021)
  • Table 77. MEA Soliris Drug, by Application USD Million (2016-2021)
  • Table 78. MEA Soliris Drug, by End-User USD Million (2016-2021)
  • Table 79. Middle East Soliris Drug, by Type USD Million (2016-2021)
  • Table 80. Middle East Soliris Drug, by Application USD Million (2016-2021)
  • Table 81. Middle East Soliris Drug, by End-User USD Million (2016-2021)
  • Table 82. Africa Soliris Drug, by Type USD Million (2016-2021)
  • Table 83. Africa Soliris Drug, by Application USD Million (2016-2021)
  • Table 84. Africa Soliris Drug, by End-User USD Million (2016-2021)
  • Table 85. North America Soliris Drug, by Country USD Million (2016-2021)
  • Table 86. North America Soliris Drug, by Type USD Million (2016-2021)
  • Table 87. North America Soliris Drug, by Application USD Million (2016-2021)
  • Table 88. North America Soliris Drug, by End-User USD Million (2016-2021)
  • Table 89. United States Soliris Drug, by Type USD Million (2016-2021)
  • Table 90. United States Soliris Drug, by Application USD Million (2016-2021)
  • Table 91. United States Soliris Drug, by End-User USD Million (2016-2021)
  • Table 92. Canada Soliris Drug, by Type USD Million (2016-2021)
  • Table 93. Canada Soliris Drug, by Application USD Million (2016-2021)
  • Table 94. Canada Soliris Drug, by End-User USD Million (2016-2021)
  • Table 95. Mexico Soliris Drug, by Type USD Million (2016-2021)
  • Table 96. Mexico Soliris Drug, by Application USD Million (2016-2021)
  • Table 97. Mexico Soliris Drug, by End-User USD Million (2016-2021)
  • Table 98. Soliris Drug: by Type(USD/Units)
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Soliris Drug: by Type(USD Million)
  • Table 105. Soliris Drug Plasma Exchange , by Region USD Million (2022-2027)
  • Table 106. Soliris Drug Plasma Infusion , by Region USD Million (2022-2027)
  • Table 107. Soliris Drug: by Application(USD Million)
  • Table 108. Soliris Drug PNH , by Region USD Million (2022-2027)
  • Table 109. Soliris Drug AHUS , by Region USD Million (2022-2027)
  • Table 110. Soliris Drug HPP , by Region USD Million (2022-2027)
  • Table 111. Soliris Drug GMG , by Region USD Million (2022-2027)
  • Table 112. Soliris Drug Other , by Region USD Million (2022-2027)
  • Table 113. Soliris Drug: by End-User(USD Million)
  • Table 114. Soliris Drug Pharmaceutical , by Region USD Million (2022-2027)
  • Table 115. Soliris Drug Hospital , by Region USD Million (2022-2027)
  • Table 116. Soliris Drug R&D labs , by Region USD Million (2022-2027)
  • Table 117. Soliris Drug Others , by Region USD Million (2022-2027)
  • Table 118. South America Soliris Drug, by Country USD Million (2022-2027)
  • Table 119. South America Soliris Drug, by Type USD Million (2022-2027)
  • Table 120. South America Soliris Drug, by Application USD Million (2022-2027)
  • Table 121. South America Soliris Drug, by End-User USD Million (2022-2027)
  • Table 122. Brazil Soliris Drug, by Type USD Million (2022-2027)
  • Table 123. Brazil Soliris Drug, by Application USD Million (2022-2027)
  • Table 124. Brazil Soliris Drug, by End-User USD Million (2022-2027)
  • Table 125. Argentina Soliris Drug, by Type USD Million (2022-2027)
  • Table 126. Argentina Soliris Drug, by Application USD Million (2022-2027)
  • Table 127. Argentina Soliris Drug, by End-User USD Million (2022-2027)
  • Table 128. Rest of South America Soliris Drug, by Type USD Million (2022-2027)
  • Table 129. Rest of South America Soliris Drug, by Application USD Million (2022-2027)
  • Table 130. Rest of South America Soliris Drug, by End-User USD Million (2022-2027)
  • Table 131. Asia Pacific Soliris Drug, by Country USD Million (2022-2027)
  • Table 132. Asia Pacific Soliris Drug, by Type USD Million (2022-2027)
  • Table 133. Asia Pacific Soliris Drug, by Application USD Million (2022-2027)
  • Table 134. Asia Pacific Soliris Drug, by End-User USD Million (2022-2027)
  • Table 135. China Soliris Drug, by Type USD Million (2022-2027)
  • Table 136. China Soliris Drug, by Application USD Million (2022-2027)
  • Table 137. China Soliris Drug, by End-User USD Million (2022-2027)
  • Table 138. Japan Soliris Drug, by Type USD Million (2022-2027)
  • Table 139. Japan Soliris Drug, by Application USD Million (2022-2027)
  • Table 140. Japan Soliris Drug, by End-User USD Million (2022-2027)
  • Table 141. India Soliris Drug, by Type USD Million (2022-2027)
  • Table 142. India Soliris Drug, by Application USD Million (2022-2027)
  • Table 143. India Soliris Drug, by End-User USD Million (2022-2027)
  • Table 144. South Korea Soliris Drug, by Type USD Million (2022-2027)
  • Table 145. South Korea Soliris Drug, by Application USD Million (2022-2027)
  • Table 146. South Korea Soliris Drug, by End-User USD Million (2022-2027)
  • Table 147. Taiwan Soliris Drug, by Type USD Million (2022-2027)
  • Table 148. Taiwan Soliris Drug, by Application USD Million (2022-2027)
  • Table 149. Taiwan Soliris Drug, by End-User USD Million (2022-2027)
  • Table 150. Australia Soliris Drug, by Type USD Million (2022-2027)
  • Table 151. Australia Soliris Drug, by Application USD Million (2022-2027)
  • Table 152. Australia Soliris Drug, by End-User USD Million (2022-2027)
  • Table 153. Rest of Asia-Pacific Soliris Drug, by Type USD Million (2022-2027)
  • Table 154. Rest of Asia-Pacific Soliris Drug, by Application USD Million (2022-2027)
  • Table 155. Rest of Asia-Pacific Soliris Drug, by End-User USD Million (2022-2027)
  • Table 156. Europe Soliris Drug, by Country USD Million (2022-2027)
  • Table 157. Europe Soliris Drug, by Type USD Million (2022-2027)
  • Table 158. Europe Soliris Drug, by Application USD Million (2022-2027)
  • Table 159. Europe Soliris Drug, by End-User USD Million (2022-2027)
  • Table 160. Germany Soliris Drug, by Type USD Million (2022-2027)
  • Table 161. Germany Soliris Drug, by Application USD Million (2022-2027)
  • Table 162. Germany Soliris Drug, by End-User USD Million (2022-2027)
  • Table 163. France Soliris Drug, by Type USD Million (2022-2027)
  • Table 164. France Soliris Drug, by Application USD Million (2022-2027)
  • Table 165. France Soliris Drug, by End-User USD Million (2022-2027)
  • Table 166. Italy Soliris Drug, by Type USD Million (2022-2027)
  • Table 167. Italy Soliris Drug, by Application USD Million (2022-2027)
  • Table 168. Italy Soliris Drug, by End-User USD Million (2022-2027)
  • Table 169. United Kingdom Soliris Drug, by Type USD Million (2022-2027)
  • Table 170. United Kingdom Soliris Drug, by Application USD Million (2022-2027)
  • Table 171. United Kingdom Soliris Drug, by End-User USD Million (2022-2027)
  • Table 172. Netherlands Soliris Drug, by Type USD Million (2022-2027)
  • Table 173. Netherlands Soliris Drug, by Application USD Million (2022-2027)
  • Table 174. Netherlands Soliris Drug, by End-User USD Million (2022-2027)
  • Table 175. Rest of Europe Soliris Drug, by Type USD Million (2022-2027)
  • Table 176. Rest of Europe Soliris Drug, by Application USD Million (2022-2027)
  • Table 177. Rest of Europe Soliris Drug, by End-User USD Million (2022-2027)
  • Table 178. MEA Soliris Drug, by Country USD Million (2022-2027)
  • Table 179. MEA Soliris Drug, by Type USD Million (2022-2027)
  • Table 180. MEA Soliris Drug, by Application USD Million (2022-2027)
  • Table 181. MEA Soliris Drug, by End-User USD Million (2022-2027)
  • Table 182. Middle East Soliris Drug, by Type USD Million (2022-2027)
  • Table 183. Middle East Soliris Drug, by Application USD Million (2022-2027)
  • Table 184. Middle East Soliris Drug, by End-User USD Million (2022-2027)
  • Table 185. Africa Soliris Drug, by Type USD Million (2022-2027)
  • Table 186. Africa Soliris Drug, by Application USD Million (2022-2027)
  • Table 187. Africa Soliris Drug, by End-User USD Million (2022-2027)
  • Table 188. North America Soliris Drug, by Country USD Million (2022-2027)
  • Table 189. North America Soliris Drug, by Type USD Million (2022-2027)
  • Table 190. North America Soliris Drug, by Application USD Million (2022-2027)
  • Table 191. North America Soliris Drug, by End-User USD Million (2022-2027)
  • Table 192. United States Soliris Drug, by Type USD Million (2022-2027)
  • Table 193. United States Soliris Drug, by Application USD Million (2022-2027)
  • Table 194. United States Soliris Drug, by End-User USD Million (2022-2027)
  • Table 195. Canada Soliris Drug, by Type USD Million (2022-2027)
  • Table 196. Canada Soliris Drug, by Application USD Million (2022-2027)
  • Table 197. Canada Soliris Drug, by End-User USD Million (2022-2027)
  • Table 198. Mexico Soliris Drug, by Type USD Million (2022-2027)
  • Table 199. Mexico Soliris Drug, by Application USD Million (2022-2027)
  • Table 200. Mexico Soliris Drug, by End-User USD Million (2022-2027)
  • Table 201. Soliris Drug: by Type(USD/Units)
  • Table 202. Research Programs/Design for This Report
  • Table 203. Key Data Information from Secondary Sources
  • Table 204. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Soliris Drug: by Type USD Million (2016-2021)
  • Figure 5. Global Soliris Drug: by Application USD Million (2016-2021)
  • Figure 6. Global Soliris Drug: by End-User USD Million (2016-2021)
  • Figure 7. South America Soliris Drug Share (%), by Country
  • Figure 8. Asia Pacific Soliris Drug Share (%), by Country
  • Figure 9. Europe Soliris Drug Share (%), by Country
  • Figure 10. MEA Soliris Drug Share (%), by Country
  • Figure 11. North America Soliris Drug Share (%), by Country
  • Figure 12. Global Soliris Drug: by Type USD/Units (2016-2021)
  • Figure 13. Global Soliris Drug share by Players 2021 (%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Alexion (United States) Revenue, Net Income and Gross profit
  • Figure 16. Alexion (United States) Revenue: by Geography 2021
  • Figure 17. Company 2 Revenue, Net Income and Gross profit
  • Figure 18. Company 2 Revenue: by Geography 2021
  • Figure 19. Company 3 Revenue, Net Income and Gross profit
  • Figure 20. Company 3 Revenue: by Geography 2021
  • Figure 21. Company 4 Revenue, Net Income and Gross profit
  • Figure 22. Company 4 Revenue: by Geography 2021
  • Figure 23. Company 5 Revenue, Net Income and Gross profit
  • Figure 24. Company 5 Revenue: by Geography 2021
  • Figure 25. Global Soliris Drug: by Type USD Million (2022-2027)
  • Figure 26. Global Soliris Drug: by Application USD Million (2022-2027)
  • Figure 27. Global Soliris Drug: by End-User USD Million (2022-2027)
  • Figure 28. South America Soliris Drug Share (%), by Country
  • Figure 29. Asia Pacific Soliris Drug Share (%), by Country
  • Figure 30. Europe Soliris Drug Share (%), by Country
  • Figure 31. MEA Soliris Drug Share (%), by Country
  • Figure 32. North America Soliris Drug Share (%), by Country
  • Figure 33. Global Soliris Drug: by Type USD/Units (2022-2027)
Some of the key companies/manufacturers profiled in the report
  • Alexion (United States)
  • Company 2
  • Company 3
  • Company 4
  • Company 5
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation